Glimepiride + Metformin Tablets

Project Image
Thumb Image

Therapeutic Indication

Type 2 diabetes mellitus (glycemic control)
Combination therapy when diet and exercise alone are insufficient
Dual mechanism: incretin enhancement + reduced hepatic glucose output
Cardiovascular and metabolic risk reduction (adjunct)
+91 85919 78885

Glimepiride + Metformin

Tablet

Vidagliptin and Metformin Hydrochloride Tablets combine a DPP-4 inhibitor and a biguanide. Vidagliptin enhances incretin activity, increasing insulin secretion and reducing glucagon levels. Metformin decreases hepatic glucose production and improves insulin sensitivity. Together, they provide effective glycemic control in type 2 diabetes mellitus.

Speciality Antidiabetic | Combination Therapy
Tags Type 2 Diabetes | Sulfonylurea | Biguanide | Glycemic Control
Strength
  • Glimepiride SR 1/2 mg
  • Metformin 500 mg
Packing Size
  • 10 Tablets

Check all Tablets Range

Click to know More

Mechanism

Glimepiride stimulates insulin release from pancreatic beta cells by closing ATP-sensitive potassium channels. Metformin decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and enhances peripheral glucose uptake. Together, they provide complementary mechanisms for improved glycemic control in type 2 diabetes.

Pharmacokinetics

  • Absorption: Glimepiride SR — gradual release; Metformin — absorbed mainly in small intestine
  • Distribution: Glimepiride — highly protein bound; Metformin — not protein bound
  • Metabolism: Glimepiride — hepatic metabolism; Metformin — not metabolized
  • Elimination: Glimepiride — renal and biliary excretion; Metformin — excreted unchanged in urine
  • Half-life: Glimepiride ≈ 5–9 hours; Metformin ≈ 6 hours

Side Effects

  • Hypoglycemia (Glimepiride)
  • Nausea
  • Diarrhea
  • Headache
  • Rare: lactic acidosis, severe hypoglycemia

Contraindication

  • Hypersensitivity to Glimepiride, Metformin, or excipients
  • Renal impairment (eGFR < 30 mL/min/1.73m²)
  • Hepatic impairment
  • Alcoholism
  • Conditions predisposing to lactic acidosis

Interaction

  • Alcohol — increases risk of lactic acidosis with Metformin
  • Beta-blockers — may mask hypoglycemia symptoms
  • Cationic drugs (e.g., cimetidine) — compete for renal tubular secretion with Metformin
  • Other antidiabetic agents — additive hypoglycemic effect

Warning and Precautions

  • Monitor renal function before and during therapy
  • Discontinue if lactic acidosis is suspected
  • Use cautiously in elderly patients
  • Monitor blood glucose regularly to avoid hypoglycemia
  • Advise patients to avoid excessive alcohol intake